The scoop on Walmart's latest health venture

Welcome to Business Insider's daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.

Hello,

Today in healthcare news: Walmart's quietly building a startup that wants to use data to help customers make healthier choices, a senior living chain is requiring employees to get shots, and Verve's building a gene-editing treatment for heart disease.

Walmart is quietly building a startup that wants to help shoppers make healthier choices

• Walmart is building a new health venture through its incubation arm Store No.8, Business Insider has learned.
• The venture, which doesn't have a name yet, will aim to help shoppers make healthier choices based on their own shopping data.
• It builds on Walmart's healthcare business, which includes clinics and pharmacies.

Read the scoop from Blake Dodge and Áine Cain here>>

A major chain of senior living facilities will require more than 10,000 workers to get COVID-19 shots

• Atria Senior Living, a large operator of independent living, assisted living, and other senior living facilities, is requiring more than 10,000 US employees to get the COVID-19 vaccine.
• Atria CEO John Moore told Business Insider that requiring the vaccine is "the responsible thing to do" to stop the spread of the coronavirus among staff and residents.
• Several other long-term care companies told Business Insider they are not mandating the coronavirus vaccine.
• Employers can require staff to give COVID-19 shots without running afoul of the law, according to federal guidance, and more employers are expected to follow in Atria's footsteps.

Read the full story from Shelby Livingston here>>

Verve is gearing up to test a gene-editing treatment that could cure heart disease. The CEO shares his 3-step vision for the one-and-done heart treatment.

• A buzzy Cambridge, Massachusetts biotech is advancing its research on a gene-editing treatment for heart disease.
• Verve Therapeutics CEO Sekar Kathiresan outlined the company's three-stage strategy to ultimately cure heart disease.
• Verve's first treatment candidate uses a next-generation gene-editing tool called base-editing to change a single letter in a person's genetic code. That edit will lower levels of bad cholesterol, the company hopes.
  

Read the full story from Andrew Dunn here>>

More stories we're reading:

• One of digital health's only dedicated early-stage venture firms just raised $200 million for its second fund. Here's how founder Lynne Chou O'Keefe plans to spend it. (Business Insider)
• Uber and Lyft are pushing for a role in vaccine rollout (The Wall Street Journal)
• Answers to your 24 most burning questions about the coronavirus vaccine, from side effects and costs to when you'll be able to get one (Business Insider)
• One of Intarcia's key investors wrote down its stake former unicorn Intarcia (Stat News)

- Lydia